Streetwise Life Sciences Tools & Diagnostics Articles


Could a FDA Warning Letter Provide a Silver Lining to This Home Care Medical Device Company?

Contributed Opinion
  ()
Maj Soueidan, cofounder of GeoInvesting, profiles his long history with a company providing medical devices for the home care market. read more >

2017 Small-Cap Biotech Watchlist Update: Up 21% at the End of Q2/17

  ()
If an investor had purchased an equal dollar amount of each company on The Life Sciences Report's 2017 Small-Cap Biotech Watchlist at the beginning of the year, that portfolio would show a gain of about 21% as of July. This is primarily due to the performance of a handful of companies that have been moving their assets farther down the development pipeline, according to the analysts who follow them. read more >

Neuromonitoring Company Founded by Former NFL Quarterback Set to Go Public

Source:   ()
Assure Holdings, an intraoperative neuromonitoring company founded by former NFL quarterback Preston Parsons, will begin trading on the TSX Venture Exchange on May 29, under the trading symbol IOM. read more >

Five Companies with Favorable Risk/Reward Profiles from the AlphaNorth Capital Conference

Source:   ()
The 4th annual AlphaNorth Capital Conference brought together over 40 emerging growth companies with top investors. In this interview with Streetwise Reports, Steve Palmer, founder and president of AlphaNorth Asset Management and a co-organizer of the conference, discusses a diverse group of companies that were selected to attend the conference, including three biotech companies. read more >

3D Signatures' TeloView Can Diagnose Alzheimer's with Cheek Swab

Source:   ()
With a swab taken from the inside of a patient's cheek, 3D Signatures' TeloView platform has demonstrated its ability to diagnose Alzheimer's disease, and also to assess whether the disease is manifesting in a mild, moderate or severe form. read more >

3D Signatures' Disruptive Technology Moving Ahead for Prostate Cancer and Hodgkin's Lymphoma

Source:   ()
3D Signatures continues to advance its cutting-edge technology for prostate cancer liquid biopsies and Hodgkin's lymphoma tests. read more >

Companies Flocking to Japan for Biotech Deals

Source: Colin Lee Novick for The Life Sciences Report  (02/01/2017)
Companies Flocking to Japan for Biotech Deals
For the last two years, Japan has been at the forefront of accelerated approval for regenerative medicine products and has seen lots of licensing and contract manufacturing deals and M&A activity. Tokyo-based Colin Lee Novick, managing director of CJ PARTNERS, surveys the landscape, discussing recent tie-ups, the effects of the recently passed 21st Century Cures Act in the U.S., and what may lie ahead. read more >

2017 Small-Cap Biotech Watchlist: Takeaways for Investors

Source:   ()
Why should investors keep an eye on these twenty small-cap biotechs in 2017? The analysts who made the selections for The Life Sciences Report's 2017 Small-Cap Biotech Watchlist laid out their rationales at the Watchlist's launch at the Biotech Showcase in San Francisco on Jan. 11. read more >

19 Companies Selected for the 2017 Small-Cap Biotech Watchlist

Source:   ()
Now in its fifth year, the 2017 Life Sciences Report Biotech Watchlist includes nineteen small-cap biotech companies selected by top analysts in the field, and will be presented at the Biotech Showcase in San Francisco in January. read more >

How Sick Will Brexit Make Biotech and Pharma?

Source: Tracy Salcedo of The Life Sciences Report  (06/29/2016)
How Sick Will Brexit Make Biotech and Pharma?
Given the uncertainty and dire economic forecasts following the Brexit vote, The Life Sciences Report has reviewed commentary from sector experts and biotech publications to help investors understand what Brexit might mean for the industry. read more >

Seven Biotech Names on the Upswing: 2016 Small-Cap Biotech Watchlist Update

Source: Tracy Salcedo of The Life Sciences Report  (03/09/2016)
Seven Biotech Names on the Upswing: 2016 Small-Cap Biotech Watchlist Update
Biotech stocks—and the stock market in general—took a dive at the beginning of 2016, headed down on macroeconomic factors such as financial instability in China. The Life Sciences Report's 2016 Small-Cap Biotech Watchlist was not immune to that movement, heading into negative territory almost from the moment the selected companies were introduced. But as the market has shown signs of rebounding, so too has the Watchlist. read more >

Circling the Globe for Uncommon Biotech Opportunities: Van Leeuwenhoeck's Marcel Wijma

Source: George S. Mack of The Life Sciences Report  (02/17/2016)
Circling the Globe for Uncommon Biotech Opportunities: Van Leeuwenhoeck's Marcel Wijma
The independent analyst, such as Van Leeuwenhoeck's Marcel Wijma, normally works in the small- and micro-cap stock universe, where the buyside and sellside rarely go. Wijma applies his small-cap expertise to shed light on overlooked biotechs from Canada, Europe and Australia that could bring huge returns to investor portfolios. read more >

Look North for Value-Priced Growth in Healthcare: StoneCastle's Bruce Campbell

Source: George S. Mack of The Life Sciences Report  (02/03/2016)
Look North for Value-Priced Growth in Healthcare: StoneCastle's Bruce Campbell
Canada encompasses healthcare-related businesses that are generating cash flow and flourishing. Bruce Campbell of StoneCastle Investment Management has managed both U.S. and Canadian portfolios: He knows both spheres, and as a hedge fund and mutual fund manager he has made a specialty in acquisitions of cash-generating healthcare companies. read more >
Management Q&A: View from the Top

Advanced Stem Cell Manufacture Saves Lives and Prints Money: Stewart Washer of Cynata Therapeutics

Managment Q&A: View from the Top
Source: Peter Byrne of The Life Sciences Report  (02/03/2016)
Stewart Washer
In this interview, Cynata's executive chairman Stewart Washer tells The Life Sciences Report why his company's technology, in studies for graft-versus-host disease, has proven itself a profit driver. read more >

The 2016 Small-Cap Biotech Watchlist Debuts at the Biotech Showcase

Source: Tracy Salcedo of The Life Sciences Report  (01/27/2016)
The 2016 Small-Cap Biotech Watchlist Debuts at the Biotech Showcase
This may prove a challenging year for small-cap biotechs, but the five analysts who selected companies for inclusion on The Life Sciences Report's 2016 Small-Cap Biotech Watchlist believe these companies have a good shot at producing innovative products in a variety of indications and producing value for investors. Discovery, it turns out, is not just about finding the cure for a particular disease; it's also about finding the companies best poised to reach that goal. read more >

Panelists Select 19 Companies for the 2016 Small-Cap Biotech Watchlist

Source: Staff of The Life Sciences Report  (12/15/2015)
Panelists Select 19 Companies for the 2016 Small-Cap Biotech Watchlist
In advance of the Biotech Showcase 2016, The Life Sciences Report has once again solicited top analysts to provide the names of innovative biotech companies that investors should keep an eye on in the upcoming year. read more >

How to Engineer a Strong Portfolio with Medtech and Biotech: Zacks' Anita Dushyanth

Source: George S. Mack of The Life Sciences Report  (11/11/2015)
How to Engineer a Strong Portfolio with Medtech and Biotech: Zacks' Anita Dushyanth
Zacks Small-Cap Research analyst Anita Dushyanth discusses small- and micro-cap specialty pharma and device names with engineering tie-ins, all of which she expects to produce exciting results for investors. read more >

Solving the R&D Investment Dilemma with Project Funding: Mark Kessel

Source: George S. Mack of The Life Sciences Report  (03/21/2013)
including Solving the R&D Investment Dilemma with Project Funding: Mark Kessel read more >
Showing Results: 1 to 18 of 18

Get Our Streetwise Reports Newsletter Free

A valid email address is required to subscribe